公开(公告)号：US20240294658A1

公开(公告)日：2024-09-05

申请号：US18551146

申请日：2022-03-18

申请人： UNIVERSITE TOULOUSE III - PAUL SABATIER ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER ,  UNIVERSITE DE MONTPELLIER ,  ARTHRITIS RECHERCHE & DEVELOPPEMENT

发明人： Pauline VACHIN ,  Pascale LOUIS-PLENCE ,  Christian JORGENSEN ,  Camille ESQUERRE ,  Cyril CLAVEL ,  Guy Bruno René SERRE ,  Eve COMBES ,  Bruno ROBERT ,  Pierre MARTINEAU

IPC分类号： C07K16/28 ,  A61K38/00 ,  C07K14/745

CPC分类号： C07K16/2896 ,  C07K14/745 ,  A61K38/00 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/732 ,  C07K2319/30

摘要： The invention relates to a hybrid molecule comprising a fibrin-derived citrullinated peptide and an antibody or antibody fragment which binds to CD38 and/or CD138, the uses of such a hybrid molecule and its method of production.

公开(公告)号：US20240307538A1

公开(公告)日：2024-09-19

申请号：US18551156

申请日：2022-03-18

申请人： UNIVERSITE TOULOUSE III - PAUL SABATIER ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER ,  UNIVERSITE DE MONTPELLIER ,  ARTHRITIS RECHERCHE & DEVELOPPEMENT

发明人： Cyril CLAVEL ,  Guy Bruno René SERRE ,  Pierre MARTINEAU ,  Nerea ALLENDE-VEGA ,  Florence APPARAILLY ,  Martin VILLALBA ,  Christian JORGENSEN

IPC分类号： A61K39/00 ,  C07K14/735 ,  C07K14/75 ,  C12N5/0783 ,  C12N5/0786

CPC分类号： A61K39/46433 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4621 ,  C07K14/70535 ,  C07K14/75 ,  C12N5/0645 ,  C12N5/0646 ,  C07K2319/30 ,  C12N2510/00

摘要： The invention relates to an immune cell comprising at least one Fc receptor on its surface, characterised in that a hybrid molecule is grafted onto the Fc receptor, said hybrid molecule comprising at least one antibody Fc fragment covalently bound to at least one fibrin-derived peptide comprising one or more citrullyl residue(s). The present invention also relates to the uses of such a grafted cell, as well as its method of production.

公开(公告)号：US20180127510A1

公开(公告)日：2018-05-10

申请号：US15574515

申请日：2016-05-20

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT REGIONAL DU CANCER DE MONTPELLIER

发明人： Emmanuelle LIAUDET-COOPMAN ,  Thierry CHARDES ,  Pierre MARTINEAU ,  Yahya ASHRAF

IPC分类号： C07K16/30 ,  C07K16/40 ,  A61P35/00

CPC分类号： C07K16/3015 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/76

摘要： The invention relates to human anti-Cath-D neutralizing monoclonal antibodies and uses thereof. More particularly, the invention relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.

公开(公告)号：US20170340734A1

公开(公告)日：2017-11-30

申请号：US15534178

申请日：2015-12-08

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT REGIONAL DU CANCER DE MONTPELLIER

发明人： Bruno ROBERT ,  Christel LARBOURET ,  Pierre MARTINEAU ,  Marie-Alix POUL

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC分类号： A61K39/39558 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863

摘要： The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.

公开(公告)号：US20220324962A1

公开(公告)日：2022-10-13

申请号：US17763746

申请日：2020-09-25

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITÉ DE MONTPELLIER ,  SORBONNE UNIVERSITÉ

发明人： André PELEGRIN ,  Bruno ROBERT ,  Pierre MARTINEAU ,  Maëva CHAUVIN ,  Myriam CHENTOUF ,  Nathalie DI CLEMENTE-BESSE

IPC分类号： C07K16/26 ,  A61P35/00

摘要： In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients' tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that anti-MIS antibody B10 inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.

公开(公告)号：US20230040928A1

公开(公告)日：2023-02-09

申请号：US17783182

申请日：2020-12-08

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITÉ DE MONTPELLIER

发明人： Andre PELEGRIN ,  Pierre MARTINEAU ,  Thierry CHARDES ,  Romain LANOTTE

IPC分类号： C07K16/32 ,  A61K47/68 ,  A61P35/00 ,  A61P15/00

摘要： The present invention relates to antibodies having specificity to HER4 and uses thereof, which are able to induce biased 4ICD routing/signaling. The inventors have isolated by antibody phage display three fully human anti-HER4 single-chain variable antibody fragment (scFv), selected on human HER4 extracellular domain, referred as C6 mAb, D5 mAb and F4 mAb and one fully human anti-HER4 scFv named H2 mAb, selected on NRG 1β1-stimulated EGFR/HER4 JMaCYT1-transfected NIH3T3 cells. In particular, the present invention relates to an isolated anti-HER4 antibody, wherein said antibody binds to an epitope of the HER4 protein.

公开(公告)号：US20190256595A1

公开(公告)日：2019-08-22

申请号：US16343889

申请日：2017-10-25

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  UNIVERSITÉ DE MONTPELLIER ,  INSTITUT JEAN GODINOT ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER

发明人： Armand BENSUSSAN ,  Bruno ROBERT ,  Pierre MARTINEAU ,  Myriam CHENTOUF ,  Anne MARIE-CARDINE ,  Jérôme GIUSTINIANI

IPC分类号： C07K16/28

摘要： The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD160 GPI-anchored isoform not to the CD160 soluble isoform. In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells.

公开(公告)号：US20150346192A1

公开(公告)日：2015-12-03

申请号：US14759193

申请日：2014-01-02

申请人： SANOFI ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  INSTITUT REGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITE DE MONTPELLIER

发明人： Piona DARIAVACH ,  Pierre MARTINEAU ,  Chang HAHN

IPC分类号： G01N33/50 ,  C07K16/18

CPC分类号： G01N33/5023 ,  C07K16/00 ,  C07K16/18 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/80 ,  G01N33/5008 ,  G01N33/6845 ,  G01N33/6854 ,  G01N2500/02 ,  G01N2500/10

摘要： The present invention relates to a method for identifying a cellular target involved in a cell phenotype comprising identifying an intrabody which can modify a cell phenotype and identifying a direct or indirect cellular target of the intrabody. The present invention also relates to intrabodies 3H2-1, 3H2-VH and 5H4 which are capable of inhibiting the degranulation reaction in mast cells triggered by an allergic stimulus, and especially to intrabodies 3H2-1 and 5H4 which are capable of directly or indirectly targeting a protein of the ABCF1 family and of the C120RF4 family respectively. The present invention also relates to ABCF1 and C120RF4 inhibitors for use in therapy, in particular for treating allergic and/or inflammatory conditions.

摘要翻译： 本发明涉及用于鉴定参与细胞表型的细胞靶标的方法，其包括鉴定可以修饰细胞表型并鉴定所述体内的直接或间接细胞靶标的体内。 本发明还涉及能够抑制由过敏刺激触发的肥大细胞中的脱颗粒反应的体内抗体3H2-1,3H2-VH和5H4，特别是能够直接或间接靶向的胞内抗体3H2-1和5H4 分别是ABCF1家族和C120RF4家族的蛋白质。 本发明还涉及用于治疗的ABCF1和C120RF4抑制剂，特别是用于治疗过敏和/或炎性病症。

公开(公告)号：US20210188983A1

公开(公告)日：2021-06-24

申请号：US16077946

申请日：2017-02-17

申请人： UNIVERSITE DE MONTPELLIER ,  INSTITUT REGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITE PARIS DIDEROT - PARIS 7

发明人： Bruno ROBERT ,  Pierre MARTINEAU ,  Alain COUVINEAU

IPC分类号： C07K16/28 ,  A61K47/68

摘要： The present invention relates to polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor. In particular, the present invention relates to a polypeptide comprising the amino acid sequence of formula of X20-X21-X22-X23-G-X25-L-X27-X28 wherein: —X20 represents N, D, or K, —X21 represents H, A or Q, —X22 represents A, S, T or G, —X23 represents A, T or G, —X25 represents I or L, —X27 represents T or V and, —X28 represents M, L, V, Y or I.

公开(公告)号：US20180002421A1

公开(公告)日：2018-01-04

申请号：US15543371

申请日：2016-01-14

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE PARIS DIDEROT - PARIS 7 ,  INSTITUT REGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITE DE MONTPELLIER

发明人： Alain COUVINEAU ,  Thierry VOISIN ,  Pascal NICOLE ,  Bruno ROBERT ,  Pierre MARTINEAU ,  Myriam CHENTOUF

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K39/00

摘要： The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.